Teledyne Agrees to Buy Varex Imaging for $18.90 a Share in Cash, a Deal Valued at About $1.1 Billion

A $1.1 Billion Bet on a Part Nobody Sees

Every CT scanner and every airport bag scanner has a beam and a sensor. The beam comes from an X-ray tube. The sensor is a detector. Teledyne Technologies, a company that makes vacuum electronics and imaging sensors, has never made the tube. On August 10, 2026, it agreed to fix that by buying the company that does^[1][2].

Teledyne will pay $18.90 in cash for every share of Varex Imaging, the Salt Lake City company that supplies those tubes and detectors to equipment makers like Canon and Siemens. Counting Varex's stock awards and its debt minus cash as of April 3, 2026, the deal totals about $1.1 billion^[1][2]. Varex closed at $12.41 the Friday before the announcement, so the offer is roughly 52% above that price. Varex shares jumped about 48% when trading opened Monday^[3][6]. Both boards approved it unanimously^[1].

Nobody disputes those numbers. What's less settled is what they mean — whether Teledyne got a bargain or paid a full price, whether regulators will see the "no overlap" story Teledyne is telling them, and whether a Chinese trade case that's been dormant since November 2025 could still complicate things before the deal closes^[5].

The Part Teledyne Says It Can't Build Itself

Robert Mehrabian, Teledyne's executive chairman, described the fit in oddly specific terms: the two companies' products are "uniquely complementary with minimal overlap"^[1]. He named three gaps. Teledyne makes X-ray detectors, but not the kind built for high-radiation settings like cancer radiotherapy — Varex does. Only Varex makes advanced photon-counting detectors. And Teledyne has never made X-ray tubes at all, for any use^[1].

Photon-counting is the term doing the most work in that pitch. A regular detector adds up all the X-ray energy hitting it and reports one brightness reading. A photon-counting detector counts each individual X-ray particle and measures its energy. That produces a sharper image at a lower radiation dose, and it can tell materials apart by their energy signature — useful for spotting plaque inside an artery, or explosives inside a suitcase^[1][7].

Building that capability from nothing takes years. Varex has been developing it since it was spun out of Varian, and it's currently the only independent supplier with a version ready to sell^[1][5][7]. Buying it is faster than building it, and Teledyne has the cash to do that without straining its balance sheet: $284.7 million in free cash flow last quarter, and debt at just 1.1 times its annual operating earnings^[9].

A Stock the Market Had Given Up On

Varex's board has a simpler case: $18.90 in cash beats what Wall Street thought the company was worth on its own. Before the deal, analysts rated the stock a "Hold," with an average price target of $18^[10]. The $18.90 offer cleared that bar. Cash also removes risk — shareholders don't have to hold Teledyne stock and hope it performs.

The board kept an escape hatch. If a better offer shows up, Varex can take it, but it would owe Teledyne a $25.3 million break fee — about 2.3% of the deal's value, low enough that it wouldn't scare off a rival bidder^[4]. Both sides also set a hard deadline: May 10, 2027. If the deal hasn't closed by then, either party can walk away^[4].

Photon-counting CT is expensive to develop and slow to reach real sales volume. Varex, at $844.6 million in annual revenue, is a company of modest size trying to fund a generational technology shift^[3][5][10]. Selling to Teledyne hands that bill to a much bigger balance sheet.

The Leverage That Doesn't Change Hands

One number cuts both ways. Varex's own annual report says its top five customers make up about 40% of its revenue, with Canon alone accounting for roughly 18%^[5]. That's real bargaining power sitting across the table — and it stays there no matter who owns Varex.

X-ray tubes and detectors are physical products with long approval cycles. Once an equipment maker designs a specific tube into a scanner, switching suppliers takes years of re-certification^[5]. That's actually most of what Teledyne is buying: not just the technology, but Varex's already-qualified spot inside thousands of existing machines. Varex ships more than 27,000 tubes and 20,000 detectors a year on that basis^[5].

Some in the industry see a downside in that same durability. Varex today is an arms-length supplier — it doesn't make finished scanners, so rivals like Canon and Siemens can buy from it without funding a competitor. Once Teledyne owns it, those customers are buying a critical part from a larger conglomerate with its own imaging ambitions^[10]. Teledyne's counter is that it doesn't build finished medical scanners either, so nothing about that arms-length relationship actually changes^[1]. No customer has objected publicly.

The Question Sitting in a Regulatory Filing

In the U.S., the deal has to clear a waiting period under the Hart-Scott-Rodino Act, during which the Justice Department or Federal Trade Commission can look for competition the merger would eliminate^[1]. Teledyne's answer, built into Mehrabian's list of what it doesn't make, is that in tubes and high-end detectors it isn't a competitor to begin with^[1].

Outside the U.S., a different question exists. In April 2025, China's Ministry of Commerce opened an investigation into imported CT X-ray tubes, covering about 10% of Varex's revenue. It suspended that investigation indefinitely in November 2025, nine months before this deal was announced. Varex discloses in its own filings that the case could still be revived^[5].

That matters because Varex has been developing CT tubes specifically for Chinese equipment makers. A U.S. defense-linked conglomerate taking ownership of that supply is a different proposition for Beijing than an independent Utah company was^[5]. The deal's timeline gives that question room to resurface — the companies expect to close in early 2027, and the outside deadline runs to May 2027^[1][4].

What the Coverage Left Out

Straight wire coverage, like Reuters, stuck to price, premium, and the stock move, with little space for Varex's customer concentration or the China exposure disclosed in its own filings^[3]. Retail-investor outlets went further in the other direction — Benzinga's headline that Teledyne "snaps up" Varex frames the buyer as decisive and the target as cheap, which is a judgment on the price dressed up as a verb^[6].

One figure floating in coverage doesn't hold up against the deal terms. Tech Times reported an "88% premium," but measured against Varex's $12.41 close the day before the announcement, the actual premium is about 52%^[3][7]. The 88% number appears to compare against Varex's share price from late May 2026, months before the deal — a different starting point than the one the companies and the wire service used, without saying so^[7].

Trade press aimed at healthcare and Asian markets picked up threads the U.S. financial press skipped almost entirely: Radiology Business dwelt on the complementary-products argument for its industry readers^[8], while outlets covering Eurasian markets framed the sale as a Western conglomerate absorbing a company enmeshed in U.S.-China supply chains^[12]. Investment commentary on Seeking Alpha, explicitly labeled as opinion, treated the strategic fit as already proven^[9]. The one thing all of that coverage shares is silence from the parties who'd know best whether the "no overlap" story holds — Varex's big customers, U.S. antitrust staff, and Chinese regulators haven't said anything yet. For now, that's a procedural pause, not an answer.